Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Da...(in the Private Securities Litigation Ref...),Health

Date:9/21/2009

in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in its pipeline, including KRX-0401 (perifosine) and Zerenex; that the Company will be able to raise additional capital in the future in order to fund its operations; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    The contact is:
     Lauren Fischer
     Director, Investor Relations
     Keryx Biopharmaceuticals, Inc.
     Tel: 212.531.5962
     E-mail: lfischer@keryx.com

'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
2. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
3. Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
4. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
5. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
6. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
8. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
9. Keryx Biopharmaceuticals Receives Nasdaq Notification
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology